Leber’s disease, most commonly referring to Leber hereditary optic neuropathy (LHON), is a genetic condition that causes rapid, painless vision loss, typically striking one eye first and then the other within weeks to months. It’s inherited through mitochondrial DNA, passed exclusively from mother to child, and affects men roughly three times more often than women. The name “Leber” has actually been applied to two different eye conditions, the other being Leber congenital amaurosis, a childhood blindness present from birth. This article focuses on LHON, the far more commonly searched condition.
How LHON Causes Vision Loss
LHON is a mitochondrial disease, meaning it stems from defects in the tiny energy-producing structures inside your cells. The optic nerve, which carries visual information from the eye to the brain, is especially energy-hungry. When mitochondria in those nerve fibers can’t produce enough energy, the fibers degenerate. This degeneration targets the central part of the optic nerve most heavily, which is why the first and most noticeable symptom is a loss of central vision rather than peripheral vision.
The process involves direct damage to nerve fibers (axonal degeneration) with only mild inflammation. This distinguishes it from many other optic nerve conditions where swelling and immune activity play larger roles. In LHON, the damage is primarily a slow energy failure that causes nerve cells to die off.
Who Gets LHON
Because LHON mutations sit on mitochondrial DNA, only mothers pass the condition to their children. A father with the mutation cannot transmit it. However, carrying the mutation doesn’t guarantee you’ll lose your vision. Many carriers live their entire lives without symptoms. Among those who do develop vision loss, men outnumber women by about 3 to 1, according to a large epidemiological study, though older literature often cited a 5:1 ratio.
The peak age for symptom onset in males falls between 14 and 26 years old. Women who develop symptoms don’t show the same concentrated age peak, and their onset tends to be more spread across age groups. The reasons for this sex difference aren’t fully understood but likely involve hormonal factors that offer some protective effect.
What Vision Loss Feels and Looks Like
Vision loss in LHON is painless, which often delays people from seeking help. It typically begins in one eye as a blurry or foggy spot in the center of your visual field. You might notice trouble reading, recognizing faces, or seeing colors accurately. Peripheral (side) vision usually remains intact, so you can still navigate a room, but the detailed central vision needed for tasks like reading or driving deteriorates quickly.
In about 97% of patients, the second eye becomes affected within one year. Most people notice it in the second eye within weeks to months of the first. Vision tends to worsen rapidly over the first few months, then stabilizes around 4 to 6 months after symptoms begin. By the one-year mark, most patients have developed optic atrophy, a permanent thinning and damage of the optic nerve.
Stages of the Disease
LHON progresses through recognizable phases. In the asymptomatic phase, a person carries the mutation but has no vision problems. An eye exam might reveal subtle changes like swollen nerve fibers or small blood vessel abnormalities around the optic disc, but these signs are easy to miss without specialized imaging.
The subacute phase covers the first six months after symptoms appear. Central vision deteriorates rapidly during this window, and this is when most people first visit an eye doctor. The dynamic phase runs from six months to one year, during which measurable changes in the eye gradually plateau. After one year, the disease enters its chronic stage, where the optic nerve shows established atrophy and vision loss is largely stable.
Environmental Triggers That Raise Risk
Not everyone who carries an LHON mutation develops vision loss, and environmental factors play a significant role in tipping the balance. Smoking is the most consistently identified risk factor for triggering symptoms in carriers, and the relationship appears to be dose-dependent: the more you smoke, the greater the risk. This effect is even more pronounced in men than in women.
Heavy alcohol use also trends toward increased risk, though the association is mainly with binge drinking rather than moderate consumption. Other proposed triggers include nutritional deficiencies, diabetes, psychological stress, head trauma, certain medications (particularly some anti-viral and anti-tuberculosis drugs), and exposure to industrial toxins. For asymptomatic carriers, avoiding smoking and heavy drinking is one of the few concrete steps that may help prevent or delay vision loss.
How LHON Is Diagnosed
Diagnosis involves a combination of genetic testing and specialized eye imaging. The definitive confirmation comes from a blood test identifying one of three primary mitochondrial DNA mutations responsible for the vast majority of cases.
Optical coherence tomography (OCT), a non-invasive scan that creates detailed cross-sectional images of the retina, provides critical information about disease stage. In healthy eyes, the retinal nerve fiber layer measures roughly 87 to 100 micrometers thick, and the ganglion cell layer (the layer of nerve cells that form the optic nerve) sits between 75 and 88 micrometers. In early LHON, a characteristic pattern emerges: the ganglion cell layer thins while the nerve fiber layer paradoxically swells, averaging around 124 micrometers. This combination is distinctive enough to help distinguish LHON from other causes of optic nerve damage.
As the disease progresses beyond 12 weeks, the nerve fiber swelling begins to resolve while the ganglion cell layer continues to thin. In the chronic phase, both layers become significantly thinner than normal. This OCT profile can even detect changes in the second eye before a person notices any vision loss there, which opens a window for earlier intervention.
Treatment Options
The primary approved treatment in Europe is idebenone, a synthetic compound related to coenzyme Q10 that helps mitochondria produce energy more efficiently. It is taken as a 300 mg pill three times daily. Clinical trials have shown meaningful results: in the LEROS trial, between 32% and 48% of treated patients achieved clinically relevant recovery, defined as gaining at least 10 letters on a standard eye chart or improving from being unable to read the chart to reading at least 5 letters. One cohort study from Wales reported recovery rates as high as 86% at peak response.
The treatment works best when started early, ideally in the subacute phase before permanent optic nerve atrophy sets in. Once the nerve fibers are gone, no current treatment can regenerate them.
Gene therapy is also in active development. A product called Lumevoq, designed to deliver a functional copy of the affected gene directly into the eye, is currently in Phase III clinical trials. It has not received marketing authorization in any country, though the U.S. FDA granted expanded access authorization for an individual patient in late 2025, and a pivotal Phase III trial is planned for the second half of 2026.
Chances of Vision Recovery
Some patients experience spontaneous recovery without treatment, though it’s unpredictable. Recovery can begin gradually over 6 months to 1 year after the initial vision loss, or it can occur suddenly as long as 10 years after onset. The likelihood of spontaneous improvement varies depending on which specific mutation a person carries, with one of the three primary mutations historically linked to better recovery odds than the others.
When recovery does happen, it typically involves a gradual clearing of the central blind spot rather than a sudden return to normal vision. Many patients regain some useful central vision, but complete restoration to pre-disease levels is uncommon. Younger patients and those with less severe initial vision loss tend to have better outcomes, though exceptions exist in both directions.